NVS
Novartis AG
NYSE · Healthcare · Drug Manufacturers - General · CH
$159.68
−2.09%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 55.6B | 54.8B | 51.7B | 46.7B | 43.5B |
| Cost of Revenue | 14.2B | 13.7B | 12.8B | 12.5B | 11.6B |
| Gross Profit | 41.4B | 41.1B | 38.9B | 34.2B | 31.9B |
| Operating Expenses | |||||
| R&D Expense | 11.3B | 10.7B | 10.0B | 11.4B | 9.2B |
| SG&A Expense | 13.1B | 13.3B | 12.6B | 12.5B | 12.2B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 16.0M | — | 1.8B | 531.0M | 2.6B |
| Total Operating Expenses | 24.4B | 24.0B | 24.4B | 24.4B | 23.9B |
| Cost and Expenses | 38.6B | 37.7B | 37.2B | 36.9B | 35.5B |
| Operating Income (EBIT) | 17.0B | 17.1B | 14.5B | 9.8B | 7.9B |
| Non-Operating | |||||
| Interest Income | — | 374.9M | 567.7M | 629.2M | 377.7M |
| Interest Expense | 1.4B | 1.2B | 1.0B | 876.1M | 834.6M |
| Net Interest Income | (1.4B) | (812.1M) | (468.7M) | (246.9M) | (456.9M) |
| Other Non-Op Income/Expense | (1.5B) | (638.3M) | (904.0M) | (646.0M) | (769.0M) |
| Non-Operating Income (excl Interest) | 76.0M | (560.9M) | (102.0M) | (209.0M) | (31.0M) |
| EBT (Pre-Tax Income) | 15.5B | 16.4B | 13.6B | 9.1B | 7.2B |
| Income Tax Expense | 2.8B | 2.4B | 1.7B | 551.0M | 1.1B |
| Bottom Line | |||||
| Net Income | 12.8B | 14.1B | 11.9B | 14.8B | 7.0B |
| Earnings from Cont. Ops | 12.7B | 14.0B | 11.9B | 8.6B | 6.0B |
| Earnings from Discont. Ops | — | — | — | 6.3B | 906.0M |
| Bottom Line Net Income | 12.8B | 14.1B | 11.9B | 14.8B | 7.0B |
| Per Share | |||||
| Basic EPS | $6.66 | $7.25 | $5.92 | $7.15 | $3.19 |
| Diluted EPS | $6.63 | $7.19 | $5.87 | $7.10 | $3.17 |
| Revenue Per Share | $29.20 | $28.27 | $25.63 | $22.47 | $19.93 |
| Shares | |||||
| Basic Shares Outstanding | 1.9B | 1.9B | 2.0B | 2.1B | 2.2B |
| Diluted Shares Outstanding | 1.9B | 2.0B | 2.0B | 2.1B | 2.2B |
| Profitability Metrics | |||||
| EBITDA | 22.3B | 23.0B | 20.7B | 18.3B | 14.7B |
| D&A | 5.3B | 5.4B | 6.1B | 8.3B | 6.7B |
| EBIT | 16.9B | 17.6B | 14.6B | 10.0B | 8.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026